Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.zenotechlab.com | |
Market Cap | 359.47 Cr. | |
Enterprise Value(EV) | 358.25 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 3.98 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 14.81 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 12.65 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 4.66 | Calculated using Price: 58.90 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 6.10 Cr. | 61,030,568 Shares |
FaceValue | 10 | |
Company Profile | ||
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world. |
1 Day |
|
-2.89% |
1 Week |
|
-0.51% |
1 Month |
|
-6.90% |
3 Month |
|
-12.06% |
6 Month |
|
+8.40% |
1 Year |
|
+7.12% |
2 Year |
|
+90.58% |
5 Year |
|
+22.04% |
10 Year |
|
+126.55% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -155.73 | -7.73 | 24.35 | -2.48 | 37.26 | |||||
Return on Capital Employed (%) | -39.28 | -61.52 | -65.68 | -61.88 | -5.95 | 18.32 | 0.48 | 15.26 | ||
Return on Assets (%) | -33.32 | -45.43 | -32.82 | -38.33 | -17.89 | -3.76 | 12.67 | -1.42 | 26.45 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 3 | -27 | -46 | -66 | 42 | 39 | 50 | 48 | 71 | 77 | |
Non Curr. Liab. | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | -4 | -8 | |
Curr. Liab. | 66 | 91 | 99 | 116 | 39 | 45 | 35 | 15 | 16 | 15 | |
Minority Int. | |||||||||||
Equity & Liab. | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 | 85 | |
Non Curr. Assets | 59 | 55 | 50 | 49 | 50 | 65 | 80 | 79 | 74 | 72 | |
Curr. Assets | 11 | 8 | 3 | 2 | 31 | 19 | 6 | 7 | 7 | 13 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 | 85 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 3 | 4 | 2 | 2 | 11 | 13 | 26 | 22 | 37 | 41 | |
Other Income | 3 | 0 | 0 | 0 | 2 | 5 | 1 | 0 | 1 | 1 | |
Total Income | 5 | 4 | 2 | 2 | 14 | 18 | 27 | 23 | 37 | 43 | |
Total Expenditure | -20 | -24 | -10 | -13 | -19 | -17 | -17 | -16 | -19 | -20 | |
PBIDT | -15 | -20 | -8 | -10 | -6 | 1 | 10 | 7 | 18 | 22 | |
Interest | -5 | -7 | -8 | -8 | -2 | 0 | -1 | -2 | -1 | -1 | |
Depreciation | -4 | -4 | -4 | -4 | -4 | -4 | -5 | -6 | -7 | -7 | |
Taxation | 12 | 10 | |||||||||
Exceptional Items | 2 | 6 | |||||||||
PAT | -23 | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 22 | 24 | |
Adjusted EPS | -6 | -8 | -5 | -5 | -2 | -1 | 2 | 0 | 4 | 4 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -10 | -24 | -8 | -5 | 2 | -16 | -14 | 11 | 6 | 18 | |
Cash Fr. Inv. | 0 | -1 | 0 | 6 | -1 | -3 | -16 | -21 | -5 | -2 | |
Cash Fr. Finan. | 10 | 30 | 7 | -1 | -1 | 47 | 15 | -3 | 0 | -16 | |
Net Change | 0 | 5 | -1 | 0 | 0 | 28 | -15 | -12 | 1 | 0 | |
Cash & Cash Eqvt | 2 | 6 | 6 | 0 | 0 | 28 | 13 | 1 | 2 | 2 |
Fri, 27 Jan 2023
Announcement under Regulation 30 (LODR)-Meeting Updates With reference to the intimation of Board Meeting submitted on January 19 2023 we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 27 2023 which commenced at 5:30 p.m. IST and ended at 7: 15 p.m. IST. The Board has inter-alia approved Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2022. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31 2022 along with the Limited Review Report thereon issued by the Statutory Auditors of the Company. |
Fri, 27 Jan 2023
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2022 With reference to the intimation of Board Meeting submitted on January 19 2023 we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 27 2023 which commenced at 5:30 p.m. IST and ended at 7:15 p.m. IST. The Board has inter-alia approved Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2022. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31 2022 along with the Limited Review Report thereon issued by the Statutory Auditors of the Company. |
Thu, 19 Jan 2023
Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2022. ZENOTECH LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2023 inter alia to consider and approve the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31 2022. |
Fri, 27 Jan 2023 |
|
|
|
|
|